Invest-CTO PCI Trial
Active, not recruitingNot applicableNCT04774913
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Following unsuccessful CTO crossing a CTO modification procedure is sometimes performed. CTO PCI registries where plaque modification has been performed in some patients, report this to be safe, and associated with higher success rates at subsequent attempts. It has never been investigated whether a planned investment procedure, with an intention that both the initial and staged completion PCI are of shorter duration, could improve safety and efficacy. The investigators hypothesize that 1. A planned investment procedure in the treatment of CTOs will be associated with improved patient safety 2. A planned investment procedure will be associated with improved cumulative procedure success rates 3. A planned two stage procedure will be associated with improved patient experience
Study details
- Official title
- Invest-CTO: Effectiveness and Safety of a Planned Investment Procedure in High-Risk CTO PCI
- Conditions
- Chronic Total Occlusion of Coronary Artery
- Angina Pectoris
- Quality of Life
- Prom
- Interventions
- Procedure: Chronic total occlusion(CTO) percutaneous coronary intervention (PCI)
- Sponsor
- Haukeland University Hospital
- Collaborators
- Golden Jubilee National Hospital
- Start date
- 2021-12-08
- Primary completion
- 2025-10-09
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Norway, United Kingdom, United States
- Total sites listed
- 5
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Ability to provide written informed consent * Comply with the procedural and study follow-up schedule * Planned CTO PCI in accordance with the European and American appropriateness criteria. * CTO defined as high-risk Exclusion Criteria: * Non-high risk CTO * Occlusion within a stent * Flush aorto-ostial occlusion of RCA and Left Main (LMS) * Limited arterial access precluding repeat procedure * Baseline non invasive testing showing non-viable target vessel territory * Contra-indication to dual antiplatelet therapy * Pregnancy * Prior radiation skin injury * Lack of informed consent
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04774913